Phase 3 N=28 Randomized Double-blind Prevention

Carnitine Supplementation and Skeletal Muscle Function

Sarcopenia

Bottom Line

View on ClinicalTrials.gov: NCT02692235 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2019

Primary outcome: Primary: Blood Inflammatory Marker — 2.6; 1.8; 2.9; 1.7 mg·L^-1

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: carnitine (Dietary_supplement); placebo (Dietary_supplement)
Age: Older Adult · 65+ yrs
Sex: All
Sponsor: Gdansk University of Physical Education and Sport
Primary completion: Mar 2017

Outcome Measures

Outcome	Result	p-value
PRIMARY Blood Inflammatory Marker	2.6; 1.8; 2.9; 1.7	—
SECONDARY Lipid Metabolites	233; 221; 221; 196; 69; 68	—

Summary

Research project objectives The primary aim of the current research project is to use carnitine supplementation as the anti-inflammatory intervention for exploring the relationship between inflammation and associated with aging reduction of skeletal muscle mass. Hypothesis The carnitine supplementation modulates the blood cytokines concentration. Anti-inflammatory intervention delay the reduction of skeletal muscle mass associated with aging

Eligibility Criteria

Inclusion Criteria

Subjects with no history of gastrointestinal disorders, cardiovascular disease or hypertension.

Exclusion Criteria

Subjects having any illnesses and a history of gastrointestinal disorder, cardiovascular disease, hypertension, liver and renal disease, diabetes, cancer, alcoholism or other metabolic diseases.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02692235). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.